Literature DB >> 10543769

Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes.

E J Goldstein1, D M Citron, C V Merriam, Y Warren, K Tyrrell.   

Abstract

The comparative activity of telithromycin (HMR 3647) against 419 human anaerobic isolates was determined by the agar dilution method. At concentrations of </=0.5 microgram/ml, telithromycin was active against Actinomyces israelii, Actinomyces odontolyticus, Bacteroides tectum, Bacteroides ureolyticus, Bacteroides gracilis (now Campylobacter gracilis), Porphyromonas spp. (including Porphyromonas gingivalis and Porphyromonas macacae), Prevotella intermedia, Prevotella heparinolytica, and almost all Peptostreptococcus species. Clostridia showed species and strain variability, often with a biphasic pattern. Fusobacterium species, except Fusobacterium russii, were relatively resistant.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10543769      PMCID： PMC89565     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  The in-vitro activity of HMR 3647, a new ketolide antimicrobial agent.

Authors:  F J Boswell; J M Andrews; J P Ashby; C Fogarty; N P Brenwald; R Wise
Journal:  J Antimicrob Chemother       Date:  1998-12       Impact factor: 5.790

2.  In vitro activity of the new ketolide HMR3647 in comparison with those of macrolides and pristinamycins against Enterococcus spp.

Authors:  C Torres; M Zarazaga; C Tenorio; A Portillo; Y Saenz; F Ruiz; F Baquero
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

3.  Comparative antianaerobic activities of the ketolides HMR 3647 (RU 66647) and HMR 3004 (RU 64004).

Authors:  L M Ednie; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Activities of HMR 3004 (RU 64004) and HMR 3647 (RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and eight other antimicrobial agents against unusual aerobic and anaerobic human and animal bite pathogens isolated from skin and soft tissue infections in humans.

Authors:  E J Goldstein; D M Citron; S Hunt Gerardo; M Hudspeth; C V Merriam
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Characterization of saccharolytic Bacteroides and Prevotella isolates from infected dog and cat bite wounds in humans.

Authors:  C J Alexander; D M Citron; S Hunt Gerardo; M C Claros; D Talan; E J Goldstein
Journal:  J Clin Microbiol       Date:  1997-02       Impact factor: 5.948

6.  In vitro evaluation of a novel ketolide antimicrobial agent, RU-64004.

Authors:  C Jamjian; D J Biedenbach; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

7.  Antimicrobial activity of RU-66647, a new ketolide.

Authors:  R N Jones; D J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  1997 Jan-Feb       Impact factor: 2.803

8.  Frequency of isolation of Porphyromonas species from infected dog and cat bite wounds in humans and their characterization by biochemical tests and arbitrarily primed-polymerase chain reaction fingerprinting.

Authors:  D M Citron; S Hunt Gerardo; M C Claros; F Abrahamian; D Talan; E J Goldstein
Journal:  Clin Infect Dis       Date:  1996-12       Impact factor: 9.079

9.  In vitro activity of HMR 3647 against anaerobic bacteria.

Authors:  C Edlund; E Sillerström; E Wahlund; C E Nord
Journal:  J Chemother       Date:  1998-08       Impact factor: 1.714

10.  In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria.

Authors:  L Martínez-Martínez; A Pascual; A I Suárez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191
  10 in total
  15 in total

1.  In vitro activities of the new ketolide HMR 3647 (telithromycin) in comparison with those of eight other antibiotics against viridans group Streptococci isolated from blood of neutropenic patients with cancer.

Authors:  F Alcaide; M A Benítez; J Carratalà; F Gudiol; J Liñares; R Martín
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Genome sequence and analysis of the oral bacterium Fusobacterium nucleatum strain ATCC 25586.

Authors:  Vinayak Kapatral; Iain Anderson; Natalia Ivanova; Gary Reznik; Tamara Los; Athanasios Lykidis; Anamitra Bhattacharyya; Allen Bartman; Warren Gardner; Galina Grechkin; Lihua Zhu; Olga Vasieva; Lien Chu; Yakov Kogan; Oleg Chaga; Eugene Goltsman; Axel Bernal; Niels Larsen; Mark D'Souza; Theresa Walunas; Gordon Pusch; Robert Haselkorn; Michael Fonstein; Nikos Kyrpides; Ross Overbeek
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

3.  Azithromycin enhances phagocytic killing of Aggregatibacter actinomycetemcomitans Y4 by human neutrophils.

Authors:  Pin-Chuang Lai; Mark R Schibler; John D Walters
Journal:  J Periodontol       Date:  2015-01       Impact factor: 6.993

Review 4.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

5.  Azithromycin concentrations in blood and gingival crevicular fluid after systemic administration.

Authors:  Pin-Chuang Lai; Weiting Ho; Nidhi Jain; John D Walters
Journal:  J Periodontol       Date:  2011-03-21       Impact factor: 6.993

6.  [Efficacy of clarithromycin in the adjuvant treatment of chronic periodontitis: a Meta-analysis].

Authors:  Yin Bai; Yuan-Liang Bai; Jing Lai; Jiao Huang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

7.  Azithromycin decreases crevicular fluid volume and mediator content.

Authors:  W Ho; T Eubank; B Leblebicioglu; C Marsh; J Walters
Journal:  J Dent Res       Date:  2010-04-16       Impact factor: 6.116

Review 8.  Ketolides--the modern relatives of macrolides : the pharmacokinetic perspective.

Authors:  Markus Zeitlinger; Claudia Christina Wagner; Birgit Heinisch
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 9.  The ketolides: a critical review.

Authors:  George G Zhanel; Michael Walters; Ayman Noreddin; Lavern M Vercaigne; Aleksandra Wierzbowski; John M Embil; Alfred S Gin; Stephen Douthwaite; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

10.  In vitro activities of telithromycin and 10 oral agents against aerobic and anaerobic pathogens isolated from antral puncture specimens from patients with sinusitis.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi Warren; Kerin L Tyrrel; Helen Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.